東方生物(688298.SH):上半年淨利預增468.76%到573.73%左右
格隆匯6月29日丨東方生物(688298.SH)公佈,經財務部門初步測算,預計2021年半年度實現歸屬於母公司所有者的淨利潤29.8億元到35.3億元,與上年同期(法定披露數據)相比,將增加24.56億元到30.06億元,同比增加468.76%到573.73%左右。
歸屬於母公司所有者的扣除非經常性損益的淨利潤29.7億元到35.2億元,與上年同期(法定披露數據)相比,將增加24.53億元到30.03億元,同比增加474.04%到580.35%左右。
業績變化的主要原因為2021年上半年受全球新冠疫情持續深入影響,公司新型冠狀病毒抗原快速檢測試紙(膠體金)繼續投入到全球新冠疫情防控事業中,符合全球疫情檢測產品需求;公司憑藉過硬的技術指標、產品質量、品牌和行業影響力,深入拓展國際市場,新冠檢測試劑銷售繼續取得重大突破,原有業務保持穩定增長,促使公司2021年上半年經營業績繼續呈現大幅度增長。及未出現非經常性損益、會計處理等重大影響因素。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.